POLYMIXIN IN ONCOLOGY CLINICAL PRACTICE

The purpose of the study was to present data on polymixin-based antibiotics with activity against infections caused by multidrug- resistant Gram-negative bacteria, such as Acinetobacter baumannii,  Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Material and methods. The review includes data from clinical as well as in vitro studies for the period 1998–2017. The search for  relevant sources was carried out in the Medline, Cochrane Library, Elibrary and other databases.

Results. The analysis of the data showed the presence of synergism and additive activity of polymyxin in combination with  carbapenems, rifampicin and azithromycin. However, experimental  data showed no direct positive correlation between combination of  polymyxim and azithromycin/ rifampicin. In clinical studies, in  hospital-acquired pneumonia, including ventilator-associated  pneumonia, the clinical response rate of polymyxin B combined with  other antibiotics ranged from 38 % to 88 %. High nephro-and  neurotoxicity of polymyxin observed in previous studies can be  explained by a lack of understanding of its toxicodynamics or the use of an incorrect dose.

Conclusion. Polymyxin B in combination with other antibiotics is a promising treatment against infectious complications caused by multidrug resistant Gram-negative bacteria.

1. Grigorievskaya Z.V., Petukhova I.N., Bagirova N.S., Shilnikova I.I., Tereshchenko I.V., Grigorievsky E.D., Dmitrieva N.V. Nosocomial infections in cancer patients: problem of increasing resistance of gram-negative microorganisms. Siberian Journal of Oncology. 2017; 16 (1): 91–97. doi: 10.21294/1814-4861-2017-16-1-91-97. [in Russian]

2. Grigorievskaya Z.V., Petukhova I.N., Dyakova S.А., Dmitrieva N.V. Epidemiology of nosocomial infections caused by highly resistant A. baumannii strains. Siberian Journal of Oncology. 2016; 15 (3): 62–66. doi: 10.21294/1814-4861-2016-15-3-62-66. [in Russian]

3. Dmitrieva N.V., Petukhova I.N., Bagirova N.S., Grigorievskaya Z.V., Dyakova S.А., Tereshchenko I.V., Sokolova Е.N. The prevalence of nosocomial microorganisms in the oncology clinic. Clinical laboratory diagnostics, 2016; 61 (9): 619–620. [in Russian]

4. Evans M.E., Feola D.J., Rapp R.P. Polymixin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33: 960–7.

5. Dmitrieva N.V., Petukhova I.N., Gromova E.G. Sepsis. Selected issues of diagnosis and treatment. Moscow: ABV-press, 2018. 161–202. [in Russian]

6. Zavascki A.P., Goldani L.Z., Li J., Nation R.L. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007; 60: 1206–121.

7. Garg S.K., Singh O., Juneja D., Tyagi N., Khurana A.S., Qamra A., Motlekar S., Barkate H. Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence. Crit Care Res Pract. 2017; 2017: 3635609. doi: 10.1155/2017/3635609.

8. Tascini C., Menichetti F., Bozza S., Del Favero A., Bistoni F. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother. 1998 Aug; 42 (2): 270–1.

9. Yoon J., Urban C., Terzian C., Mariano N., Rahal J.J. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug- resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004 Mar; 48 (3): 753–7.

10. Manikal V.M., Landman D., Saurina G., Oydna E., Lal H., Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000; 31: 101–6.

11. Bratu S., Tolaney P., Karumudi U., Quale J., Mooty M., Nichani S., Landman D. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymixin B and othere agents. J Antimicrob Chemother. 2005; 56: 128–32.

12. Landman D., Bratu S., Alam M., Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin. B. J Antimicrob Chemother. 2005; 55: 954–7.

13. Ouderkirk J.P., Nord J.A., Turett G.S., Kislak J.W. Polymyxin B nephrotoxicitry and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother. 2003 Aug; 47 (8): 2659–62.

14. Sobieszczyk M.E., Furuya E.Y., Hay C.M., Pancholi P., Della-Latta P., Hammer S.M., Kubin C.J. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother. 2004; 54: 566–9.

15. Holloway K.P., Rouphael N.G., Wells J.B., King M.D., Blumberg H.M. Polymyxin B and doxycycline use in patients with multidrugresistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother. 2006; 40: 1939–45.

16. Zavascki A.P., Barth A.L., Fernandes J.F., Moro A.L., Gonçalves A.L., Goldani L.Z. Reappraisal of Pseudomonas aeruginosa hospitalacquired pneumonia mortality in the era of metallo-β-lactamase-mediated multidrug resistance: a prospective observational study. Crit Care. 2006; 10: R114.

17. Pereira G.H., Muller P.R., Levin A.S. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis. 2007; 58: 235–40.

18. Ostronoff M., Ostronoff F., Sucupira A., Souto Maior A.P., Caniza M., Florêncio R., Domingues M.C., Calixto R., Matias K. Multidrug-resistant Pseudomonas aeruginosa infection in neutropenic patients successfully treated with a combination of polymyxin B and rifampin. Int J Infect Dis. 2006; 10: 339–40.

19. Crusio R., Rao S., Changawala N., Paul V., Tiu C., van Ginkel J., Chapnick E., Kupfer Y. Epidemiology and outcome of infections with carbapenem-resistant gram- negative bacteria treated with Polymyxin Bbased combination therapy. Scandinavian Journal of Infectious Diseases. 2014; 46 (1): 1–8.

20. Li J., Nation R.L., Turnidge J.D., Milne R.W., Coulthard K., Rayner C.R., Paterson D.L. Colistin : re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancey Inbfect Dis. 2006; 6: 589–60.

21. Falagas M.E., Kasiakou S.K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10: R27.

22. Evagelopoulou P., Katsaros A., Myrianthefs P., Karatzas S., Boutzouka E., Fildissis G., Baltopoulos G. Colistin and rhabdomyolysis: a causative agent or an innocent bystander. Intensive Care Med. 2007; 33: 556–7.

23. Kazy Z., Puho E., Czeizei A.E. Parenteral polymyxin B treatment during pregnancy. Reprod Toxicol. 2005; 20: 181–2.